The U.S. Food and Drug Administration (FDA) recently approved Aimovig, a preventative migraine treatment for adults. Aimovig blocks the activity of the calcitonin gene-related peptide, a molecule that has been linked to migraine attacks. It is administered via monthly self-injections, and to date, has delivered safe, effective results across three clinical trials.
In an initial study of 955 migraine patients conducted over six months, Aimovig-treated patients experienced one to two fewer monthly migraine days than other study participants. Meanwhile, in a second Aimovig study of 577 migraine patients over a three-month period, Aimovig-treated patients experienced one fewer migraine days per month than other participants. In a third study of 667 chronic migraine sufferers, Aimovig-treated patients experienced 2.5 fewer monthly migraine days over a three-month period than patients who received a placebo.
Additionally, the side effects associated with Aimovig appear to be minimal. In the aforementioned Aimovig clinical trials, the most common side effects reported were injection site reactions and constipation.
It may be only a matter of time before other preventative migraine medications obtain FDA approval. The New York Times reports pharmaceutical companies Lilly, Teva and Alder have preventative migraine medications similar to Aimovig in the final stages of study or awaiting approval by the FDA.
Can Aimovig Stop All Migraines, at All Times?
Aimovig is a step in the right direction in terms of helping migraine sufferers alleviate migraine pain. It may help migraine patients address their migraine symptoms, and ultimately, prevent such problems from recurring.
Although Aimovig offers significant potential, it is important to note that preventative migraine medication may not be right for every migraine patient, every time. Today, many over-the-counter (OTC) and prescription medications are available to help migraine sufferers address migraine pain. Yet the effects of each migraine medication vary based on the individual.
If a person is experiencing vomiting, nausea, abdominal pain and other migraine symptoms, it is important to meet with a primary care doctor or neurologist. Then, this medical professional can provide a migraine evaluation and diagnosis and help a patient determine which medications can help him or her alleviate migraine pain.
Unfortunately, migraine medications sometimes fail to help a migraine sufferer address migraine pain. They may also cause a migraine patient to experience unwanted side effects. In either of these instances, a migraine sufferer may need to seek alternative migraine treatments.
Dr. Jonathan Cabin of The Migraine Institute offers migraine treatments that provide long-lasting migraine relief. He assists patients who have received a chronic migraine diagnosis and find that their current migraine medications are ineffective, and helps these individuals determine the best way to reduce or eliminate migraine pain.
As a head and neck surgeon with dual-subspecialty training in facial plastic and reconstructive surgery, Dr. Cabin takes a personalized approach to migraine treatments. First, he performs a comprehensive patient evaluation. Dr. Cabin examines a patient’s medical history and conducts a series of test to identify his or her anatomical migraine triggers. Next, he may recommend Botox® injections or minimally invasive migraine surgery tailored to a patient’s migraine triggers. Dr. Cabin also collaborates with a patient, ensuring he or she feels comfortable with a migraine treatment. To schedule a migraine consultation with Dr. Cabin, please contact us today at 310.461.0303.